On November 5, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, reported that clinical data on its BTK inhibitor BRUKINSA (zanubrutinib) and non-clinical data on its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and four posters at the 62nd American Society for Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place virtually on December 5-8, 2020 (Press release, BeiGene, NOV 5, 2020, View Source [SID1234570181]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BeiGene is co-sponsoring a satellite symposium entitled Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes, to be held on Friday, December 4 at 3:00 p.m. PT; registration for the symposium can be accessed at View Source
Oral Presentation:
Title:
Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial
Publication #:
339
Session Title:
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Clinical studies in Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia
Date and Time:
Sunday, December 6, 2020 at 10:15 a.m. PT
Presenter:
Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Australia
Poster Presentations:
Title:
Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial
Publication #:
2940
Session Title:
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Date:
Monday, December 7, 2020 at 7:00 a.m. PT
Presenter:
Gang An, M.D., Ph.D., Chinese Academy of Medical Sciences, Blood Diseases Hospital, China
Title:
Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
Publication #:
2947
Session Title:
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Date:
Monday, December 7, 2020 at 7:00 a.m. PT
Presenter:
Mazyar Shadman, M.D., MPH, Fred Hutchinson Cancer Research Center, University of Washington
Title:
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
Publication #:
1306
Session Title:
642. CLL: Therapy, excluding Transplantation: Poster I
Date:
Saturday, December 5, 2020 at 7:00 a.m. PT
Presenter:
Jennifer R. Brown, M.D., Ph.D., Dana-Farber Cancer Institute
Title:
Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action
Publication #:
1116
Session Title:
622. Lymphoma Biology—Non-Genetic Studies: Poster I
Date:
Saturday, December 5, 2020 at 7:00 a.m. PT
Presenter:
Yuqin Song, M.D., Ph.D., Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), China